**Table 1-source data 2**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **All patients**  **38 pts** | **p-value** |
| **At CRPC biopsy** | **Age, yr** |  |  |
| Median | 70.0 | 0.19a |
| IQR | 65.7-75.0 |  |
| **Sites of metastasis, n (%)** |  |  |
| Node only | 2 (5) | 0.04b |
| Bone only | 29 (76) |  |
| Visceral (with/without bone) | 7 (18) |  |
| **ECOG PS, n (%)** |  |  |
| 0 | 9 (24) | 0.25b |
| 1 | 27 (71) |  |
| 2 | 2 (5) |  |
| **PSA, μg/L** |  |  |
| Median | 242.0 | 0.68a |
| IQR | 120.0-664.8 |  |
| **Hemoglobin, g/L** |  |  |
| Mean | 112.8 | 0.55a |
| SD | 13.8 |  |
| **Alkaline phosphatase, U/L** |  |  |
| Median | 144.5 | 0.10a |
| IQR | 82.5-347.5 |  |
| **Lactate dehydrogenase, U/L** |  |  |
| Median | 190.0 | 0.67a |
| IQR | 149.3-259.5 |  |
| **Albumin, g/L** |  |  |
| Mean | 34.1 | 0.02a |
| SD | 4.3 |  |
| **Treatments prior to/on for CRPC at biopsy, n (%)** |  |  |
| Docetaxel | 23 (61) | 0.80a |
| Abiraterone | 19 (50) | 0.37a |
| Enzalutamide | 3 (8) | 0.18a |
| Cabazitaxel | 6 (16) | 0.41a |
| **Treatment for CRPC after biopsy, n (%)** |  |  |
| Docetaxel | 12 (32) | 0.94a |
| Abiraterone | 19 (50) | 0.37a |
| Enzalutamide | 6 (16) | 0.82a |
| Cabazitaxel | 15 (39) | 0.14a |